The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 2 study of immunogenic cell death inducer PT-112 in patients with metastatic castration-resistant prostate cancer.
 
Alan Haruo Bryce
Honoraria - Advanced Accelerator Applications/Novartis; Astellas Pharma; AstraZeneca; Bayer; Castle Biosciences; Horizon CME; Myovant Sciences; Myovant Sciences; Pfizer; Research to Practice; Research to Practice; Verity Pharmaceuticals
Travel, Accommodations, Expenses - Clovis Oncology (Inst); Phosplatin Therapeutics (Inst)
 
Daniel D. Karp
Research Funding - Phosplatin Therapeutics (Inst)
Travel, Accommodations, Expenses - Phosplatin Therapeutics
 
Scott T. Tagawa
Consulting or Advisory Role - 4D Pharma; Abbvie; AIkido Pharma; Amgen; Astellas Pharma; Bayer; Blue Earth Diagnostics; Clarity Pharmaceuticals; Clovis Oncology; Convergent Therapeutics; Dendreon; Endocyte; Genentech; Genomic Health; Gilead Sciences; Immunomedics; Janssen; Karyopharm Therapeutics; Medivation; Myovant Sciences; Novartis; Pfizer; POINT Biopharma; QED Therapeutics; Sanofi; Seagen; Telix Pharmaceuticals; Tolmar
Research Funding - Abbvie (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); AVEO (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Dendreon (Inst); Endocyte (Inst); Exelixis (Inst); Genentech (Inst); Immunomedics (Inst); Inovio Pharmaceuticals (Inst); Janssen (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Medivation (Inst); Merck (Inst); Millennium (Inst); Newlink Genetics (Inst); Novartis (Inst); POINT Biopharma (Inst); Progenics (Inst); Rexahn Pharmaceuticals (Inst); Sanofi (Inst); Stem CentRx (Inst)
Patents, Royalties, Other Intellectual Property - Patent Royalty from Immunomedics / Gilead
Travel, Accommodations, Expenses - Amgen; Immunomedics; Sanofi
(OPTIONAL) Uncompensated Relationships - ATLAB Pharma; Phosplatin Therapeutics
 
Luke T. Nordquist
No Relationships to Disclose
 
Dana E. Rathkopf
Consulting or Advisory Role - AstraZeneca; Bayer; Genentech; Janssen; Myovant Sciences
Research Funding - AstraZeneca (Inst); Bayer (Inst); Celgene (Inst); Ferring (Inst); Genentech/Roche (Inst); Janssen Oncology (Inst); Medivation (Inst); Millennium (Inst); Novartis (Inst); Phosplatin Therapeutics (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); TRACON Pharma (Inst)
 
Nabil Adra
Consulting or Advisory Role - Astellas Pharma; Aveo; Bristol Myers Squibb Foundation; Bristol Myers Squibb Foundation; Exelixis; Merck; Sanofi
Research Funding - Exelixis (Inst); Genentech (Inst); Merck (Inst); Natera (Inst)
 
Tanya B. Dorff
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Exelixis; Janssen Oncology; Pfizer; Seagen
Research Funding - Pfizer (Inst)
 
Johan Baeck
Employment - Jounce Therapeutics; Promontory Therapeutics
Leadership - Promontory Therapeutics
Stock and Other Ownership Interests - Jounce Therapeutics; Promontory Therapeutics
Travel, Accommodations, Expenses - Jounce Therapeutics; Promontory Therapeutics
Other Relationship - Jounce Therapeutics; Promontory Therapeutics
 
Joseph Francis O'Donnell
Employment - Promontory Therapeutics
Leadership - Promontory Therapeutics
Stock and Other Ownership Interests - Promontory Therapeutics
 
Tyler David Ames
Employment - Promontory Therapeutics
Stock and Other Ownership Interests - Promontory Therapeutics
Patents, Royalties, Other Intellectual Property - I am an inventor on some patents pertaining to the mechanism or use of PT-112, an anticancer compound being developed by my employer Promontory Therapeutics.
Travel, Accommodations, Expenses - Promontory Therapeutics
 
Christina Y. Yim
Employment - Promontory Therapeutics
Stock and Other Ownership Interests - Promontory Therapeutics
Travel, Accommodations, Expenses - Promontory Therapeutics
 
Matthew Price
Employment - Promontory Therapeutics
Leadership - Promontory Therapeutics
Stock and Other Ownership Interests - Promontory Therapeutics
Patents, Royalties, Other Intellectual Property - US Patents 10,668,080 and 11,438,619 assigned to Promontory Therapeutics
Travel, Accommodations, Expenses - Promontory Therapeutics
 
Howard I. Scher
Honoraria - Arsenal Capital; Elsevier; Sidney Kimmel Cancer Center- Jefferson Health
Consulting or Advisory Role - Bayer; Janssen Research & Development; Pfizer; Sanofi; Sun Pharma; WIRB-Copernicus Group
Research Funding - AIQ Solutions (Inst); Epic Sciences (Inst); Illumina (Inst); Janssen (Inst); Menarini Silicon Biosystems (Inst); Thermofisher Scientific Biomarkers (Inst)
Patents, Royalties, Other Intellectual Property - BioNTech -Intellectual Property Rights; Elucida Oncology - Intellectual Property Rights; MabVAX - Intellectual Property Rights; Y-mAbs Therapeutics, Inc - Intellectual Property Rights
Travel, Accommodations, Expenses - Bayer; Biodesix; Epic Sciences; Promontory Therapeutics; Prostate Cancer Foundation; WIRB-Copernicus Group